Logo Image
Opinion|Videos|October 11, 2024

Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

Key Takeaways

  • Belimumab and voclosporin have unique mechanisms of action, impacting their efficacy and safety profiles in lupus nephritis treatment.
  • Payers consider clinical outcomes, cost, and value when evaluating belimumab and voclosporin for lupus nephritis management.
SHOW MORE

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

Episodes in this series

What is your perspective on the differences between the efficacy and safety profiles of belimumab and voclosporin in the treatment of lupus nephritis (LN)? (Dr. Larranaga and Dr. Wells)

How are payers evaluating the value of belimumab and voclosporin in the management of LN? (Dr. Wigginton)

  • What does cost-effectiveness look like in LN management?

Related Content